WorksheetsBiso + Telmi PK & POA MCQs
Total questions: 30
Worksheet time: 30mins
Bisoprolol is classified as:
Non-selective beta blocker
Highly selective Beta-1 adrenoceptor antagonist
Alpha blocker
Calcium channel blocker
Bisoprolol's selectivity for beta-1 receptor is:
5-fold higher than beta-2
10-fold higher than beta-2
19-fold higher than beta-2
25-fold higher than beta-2
Which generation of beta blocker is Bisoprolol?
First-generation
Second-generation
Third-generation
Fourth-generation
Bisoprolol has been available worldwide for:
10 years
20 years
35 Years
40 years
Bisoprolol's mechanism in hypertension involves blocking beta1 receptors in:
Heart only
Juxtaglomerular cells
Lungs
Kidneys only
The duration of action of Bisoprolol is:
8 hours
12 hours
24 hours
48 hours
Bisoprolol's intrinsic sympathomimetic activity is:
High
Moderate
Low
No intrinsic sympathomimetic activity
What percentage of Bisoprolol undergoes renal elimination unchanged?
25%
50%
75%
100%
What percentage of Bisoprolol undergoes hepatic metabolism?
25%
50%
75%
100%
Dose adjustment of Bisoprolol is necessary in:
Mild to moderate liver impairment
Mild to moderate kidney impairment
Both mild to moderate liver and kidney impairment
No dose adjustment necessary in mild to moderate impairment
The therapeutic dose range of Bisoprolol for mild-to-moderate essential hypertension is:
2.5-10 mg
5-20 mg
10-40 mg
20-80 mg
Bisoprolol's effect on lipid and glucose metabolism is:
Adverse effects on both
Improves both
Metabolically neutral
Improves lipids but worsens glucose
Bisoprolol's effect on airway resistance is:
Significant bronchospasm
Moderate effect
Minimal effect
No effect at all
Bisoprolol's effect on sexual function is:
Significant impairment
Moderate impairment
Minimal effect
Improves sexual function
Bisoprolol's pharmacokinetic variability compared to other beta-blockers is:
Higher
Similar
Lower
Unpredictable
Telmisartan is an antagonist of:
Beta-1 receptors
Angiotensin II type 1 (AT1) receptors
Alpha receptors
Calcium channels
Telmisartan's binding to AT1 receptor is:
Competitive and reversible
Non-competitive and irreversible
Insurmountable but reversible
Competitive and irreversible
In terms of AT1 receptor binding affinity, the rank order is:
Losartan > Telmisartan > Olmesartan
Telmisartan > Olmesartan > Candesartan > Valsartan ≥ Losartan
Olmesartan > Telmisartan > Candesartan
Valsartan > Telmisartan > Losartan
Telmisartan's affinity for AT2 receptor is:
High
Moderate
Low
Minimal
Telmisartan is characterized as:
Hydrophilic
Highly lipophilic
Neither hydrophilic nor lipophilic
Moderately hydrophilic
The terminal elimination half-life of Telmisartan is approximately:
12 hours
18 hours
24 hours
36 hours
Telmisartan modulates which receptor that's important in metabolic disorders?
PPARα
PPARγ (Peroxisome proliferator-activated receptor γ)
PPARδ
None of the above
The onset of antihypertensive effects of Telmisartan occurs within:
1 hour
3 hours
6 hours
12 hours
Telmisartan significantly reduces:
Only diastolic BP
Only systolic BP
Early morning systolic BP surge
Heart rate only
In the GEMINI trial, adding β-blockers to ACEi or ARBs achieved adequate BP control in what percentage of diabetic hypertensive patients?
30%
Almost 40%
50%
60%
Telmisartan's high lipophilicity benefits:
Only oral absorption
Only systemic RAS blockade
Tissue and cell penetration, blocking both systemic and local RAS
Only renal elimination
Telmisartan is effective in reducing target-organ damage including:
Only cardiac changes
Only renal changes
Endothelial dysfunction, arterial stiffness, renal dysfunction, proteinuria, and LV hypertrophy
Only vascular changes
In uncomplicated and complicated hypertension, Telmisartan:
Only reduces BP
Favors regression of cardiac and vascular organ damage
Only improves symptoms
Has no effect on organ damage
Telmisartan's effect on arterial stiffness is:
Increases stiffness
No effect on stiffness
Reduces arterial stiffness and improves vascular distensibility
Only affects large arteries
The combination of BB and ARB is particularly useful because both drug classes are:
Nephrotoxic
Hepatoprotective
Cardio-protective
Bronchodilator
